Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding

  • Intersect ENT Inc XENT expects Q2 sales of approximately $27.3 million, slightly below the consensus estimate of $28.02 million.
  • Record quarterly revenue from the Sinuva sinus implant is approximately $2.7 million.
  • The quarter ended with cash, cash equivalents, restricted cash, and short-term investments of approximately $76.2 million.
  • The Company reiterates full-year 2021 revenue guidance of $117 million - $121 million.
  •  "While elective sinus procedures continue to trend positively, the recovery in procedures has only returned to approximately 90%-95% of pre-COVID levels. Looking ahead, we expect a return to normalized procedure rates in the second half of 2021," said Thomas A. West, President & CEO.
  • Intersect ENT entered a $60 million secured term loan agreement with Deerfield Management Company LP, structured in three $20 million tranches over the next three years. 
  • The Company will release full Q2 2021 financial results on August 6.
  • Price Action: XENT shares are down 0.71% at $19.50 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsNewsGuidanceHealth CareFinancingSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!